Stem Cell Clinic

Alpha Thalassemia Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted By the Competitors |…

By Gene Therapy Clinics

Global Alpha Thalassemia Market 2025 Report Provides Porters Five Forces Analysis Illustrates the Potency of Buyers & Suppliers Operating in the Industry & the Quantitative Analysis of The Global Market from 2019 to 2025 is Provided to Determine the Market Potential.

Alpha Thalassemia Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025 The study of Alpha Thalassemia market is a compilation of the market of Alpha Thalassemia broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Alpha Thalassemia industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Alpha Thalassemia industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Request a sample of Alpha Thalassemia Market report @ https://hongchunresearch.com/request-a-sample/61906

The following manufacturers are covered: Bluebird Bio Novartis Kiadis Pharma Acceleron Pharma

Access this report Alpha Thalassemia Market @https://hongchunresearch.com/report/worldwide-alpha-thalassemia-market-2019-61906

Segment by Regions North America Europe China Japan

Segment by Type Iron Chelating Drugs Gene Therapy

Segment by Application Hospitals Private clinics Other

For a global outreach, the Alpha Thalassemia study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses: Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitions Revenue, cost price, capacity & utilizations, import/export rates and market share Forecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Alpha Thalassemia Market @ https://hongchunresearch.com/check-discount/61906

Major Point of TOC:

Chapter One: Alpha Thalassemia Market Overview

Chapter Two: Global Alpha Thalassemia Market Competition by Manufacturers

Chapter Three: Global Alpha Thalassemia Production Market Share by Regions

Chapter Four: Global Alpha Thalassemia Consumption by Regions

Chapter Five: Global Alpha Thalassemia Production, Revenue, Price Trend by Type

Chapter Six: Global Alpha Thalassemia Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Alpha Thalassemia Business

Chapter Eight: Alpha Thalassemia Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Alpha Thalassemia Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach 13.1.1 Research Programs/Design 13.1.2 Market Size Estimation 13.1.3 Market Breakdown and Data Triangulation 13.2 Data Source 13.2.1 Secondary Sources 13.2.2 Primary Sources 13.3 Author List 13.4 Disclaimer

About HongChun Research: HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details: Jennifer Gray Manager Global Sales + 852 8170 0792 [emailprotected]

Read this article:
Alpha Thalassemia Market Research Provides an In-Depth Analysis on the Future Growth Prospects and Industry Trends Adopted By the Competitors |...

Intrathecal Pumps Market 2020 Industry Size and Share Evolution to 2026 by Growth Insight, Trends – The Daily Philadelphian

By Gene Therapy Clinics

The Global Intrathecal Pumps Market to gain from rapid technological advancements taking place in the market. Recently Fortune Business Insights has published a report, titled Intrathecal Pumps Market Size, Share and Global Trend By Medication (Baclofen, Hydromorphone Morphine, Clonidine, Midazolam, Bupivacaine, Ziconotide), By Application (Pain Management, Spasticity Management), By End Users (Hospitals & Clinics, Ambulatory Surgery Centers, Others), and Geography Forecast till 2026

Market Segmentation:

By Medication

By End Users

Reasons to Purchase this Report:

Asthma Treatment Market

Legionella Testing Market

Anti-Fungal Drugs Market

Sleep Apnea Devices Market

Impact of COVID-19 on the Medical Devices Market

Cancer Cachexia Market

Gene Therapy Market

Human Insulin Market

Antithrombin Market

Dermatitis Drugs Market

Visit link:
Intrathecal Pumps Market 2020 Industry Size and Share Evolution to 2026 by Growth Insight, Trends - The Daily Philadelphian

$30 billion to fight COVID-19 over next five years – Sydney Morning Herald

By Gene Therapy Clinics

NSW will commit $29.6 billion to a COVID-19 health and economic package over the next five years following unprecedented emergency health spending to weather the pandemic.

Treasury forecasters are working on an assumption that a vaccine will be available by mid-next year, with an estimated 20 per cent of people vaccinated by October.

NSW will spend a total of $1.6 billion on COVID-19 programs in 2020-2021 including $500 million to support COVID clinics, quarantine programs, extra pathology testing and contact tracing.Credit:Getty/Lisa Maree Williams

Social distancing restrictions are likely to be maintained until a vaccine is widely available and most of the population immunised.

Up to $1.6 billion of the COVID-19 response budget will be used for 2020-2021 health programs, including $500 million to support clinics, quarantine programs, extra pathology testing and contact tracing.

More than $458 million will be used to fast track elective surgeries delayed by the pandemic and $20 million will accelerate COVID-specific research and clinical trials.

Some $385 million will be used to purchase additional personal protective equipment.

Loading

Treasurer Dominic Perrottet described the mental health toll as one of the pandemics most insidious hidden costs.

More than $66 million will fund additional mental health clinicians and peer workers, expanding the Police, Ambulance and Clinical Early Response model, enhancing therapeutic activities in inpatient units, increasing capacity and responsiveness of the Mental Health line and expanding virtual mental health services

Overall health spending accounted for one third of the total NSW Budget, Health Minister Brad Hazzard said.

It included $66 million over three years beginning in 2021-22 to fund additional specialist mental health clinicians. Almost $56 million over four years will go to end of life and palliative care, including 5000 additional non-clinical End of Life Support, specialist allied health professionals, education and training, and bereavement and psychosocial support services.

Almost $50 million in 2020-2021 will fund access to lifesaving cell and gene therapies, including CAR T-cell therapy for children and young adults with acute lymphoblastic leukaemia, adults with diffuse large B-cell lymphoma, as well as gene therapy services for blinding eye disease and children with spinal muscular atrophy, and monoclonal antibody therapy for children with neuroblastoma.

A $17 million-pilot program will provide in-home care for pregnant women suffering from hyperemesis gravidarum (severe morning sickness), and Tresillian and Karitane will receive more than $10 million over four years to extend virtual residential parenting services.

There is $10 million over four years to plan and undertake a NSW stroke ambulance pilot project geared towards rapid diagnosis and treatment of strokes.

The governments hospital building boom over the past several years continues. Treasurer Dominic Perrottet said the 29 upgraded hospitals and health facilities announced before the 2019 election would be under way before March 2023.

The Australian Medical Association NSW said it was concerned by the state government's continued emphasis on funding health infrastructure over current funding for staffing and resourcing.

Loading

"Hospitals and healthcare staff are struggling to meet patient demand," AMA NSW President Dr Danielle McMullen said.

The recent concerns raised about resourcing and services at Blacktown Hospital highlight the importance of funding all hospitals appropriately," she said.

Dr McMullen was also concerned funding to fast track elective surgeries wont move the needle enough to improve patient access.

We can see that access is deteriorating and wait times are getting worse," she said. "Patients are waiting more than a year for elective surgery in some cases and we know these figures only tell half the story.

Get our Coronavirus Update newsletter for the day's crucial developments and the numbers you need to know. Sign up toThe Sydney Morning Herald'snewsletterhereandThe Age'shere.

Kate Aubusson is Health Editor of The Sydney Morning Herald.

Read more here:
$30 billion to fight COVID-19 over next five years - Sydney Morning Herald

Community Cord Blood Banking saves life of child with aplastic anaemia – The Hindu

By Stem Cell Doctors

Community Cord Blood Banking, a stem cell banking initiative introduced by LifeCell in 2017, has helped save the life of a seven-year-old girl from Nashik in Maharashtra who was suffering from aplastic anaemia, a rare and serious blood disorder.

In a major breakthrough, a team of senior doctors from LOTUS Institute of Haematology, Oncology and Bone Marrow Transplantation, recently conducted Indias first dual cord blood transplant through an unrelated donor using Community Stem Cell Banking. People familiar with the development said the transplant was challenging because no apt bone marrow donors were available and the cost of retrieval of matching units from public cord blood banks would have been high.

The girls parents, as members of LifeCell Community Bank, placed a request for two matching cord blood units after the childs sibling was found to be only a 50% (4/8) match. Two high-quality matches (7/8) were found in the registry, which fulfilled the requirement for umbilical cord blood transplantation. The parents could withdraw the matched units at no extra expense, which would have cost around 45 lakh per unit.

Mayur Abhaya, MD, LifeCell International said, The purpose of Community Cord Blood Banking is to ensure easy and rapid access to stem cells for every Indian without the hurdles of public and private banking models. While stem cells from the umbilical cord blood can be procured from global public banks, the probability of finding a match for a patient of Indian origin is less than 10% because of the low inventory of available units plus the big issue of donor dropouts.

Mr. Abhaya said, Luckily, since the family was a part of LifeCells community banking programme, they could gain quick, free access to the huge inventory of over 50,000 qualified and consented units available at LifeCell, which provides greater than 97% probability of finding a match.

In majority of blood-related disorders treatable by transplants, patients own stem cells are not suitable. Hence, the best donor is a close family member, usually a sibling. However, in this case, there was only a 50% match with the sibling, thus needing a match from an unrelated donor, LifeCell said in a statement. It said while a regular stem cell transplant requires a dose of 25 million cells per kg of the patients weight, for aplastic anaemia, the recommended minimum dose is 40 million cells per kg, which is not easy to find.

The community banking model made it possible and the child received a timely transplant with an encouraging prognosis. Just 18 days after the transplant, white blood cells were completely engrafted, and platelets and red blood cell production also increased drastically, the statement added.

Dr. Pritesh Junagade, director, LOTUS Hospital, expressed surprise that the retrieval process for two cord blood units was smooth and at no additional cost to the patient as compared to other banking models.

Tasneem Bohari, the childs father, said: It was two years ago that my daughter was diagnosed with aplastic anaemia. At the time of diagnosis, the doctors had suggested she would need a stem cell transplant eventually and it would be the best possible treatment in the future.

The family did research and made enquiries about which stem cell bank to opt for as they were expecting their second child. It was during this time that their friends and relatives suggested LifeCell to them. Their doctor also suggested that they could go ahead and preserve their babys stem cell with LifeCell.

At the time of preservation, we didnt have much idea about Community Stem Cell Banking and its benefits, but today we are happy to associate with LifeCell, who have helped my daughter lead a quality life through cord blood transplant, Mr. Bohari said.

Community Cord Blood Banking allows sharing of preserved umbilical cord stem cells from a common pool amongst the members of the community. The model offers greater and easier access to donor stem cells, unlimited retrievals at the cost of one enrolment, and a higher probability for finding a close match for potentially life-saving treatments.

This facility ensures complete protection to the child, siblings, parents, and maternal and paternal grandparents from more than 80 disorders treatable by stem cells.

See original here:
Community Cord Blood Banking saves life of child with aplastic anaemia - The Hindu

Arya Lloyd: Father launches global search for blood stem cell donor to save his 12-year-old daughter – Sky News

By Stem Cell Doctors

A surgeon has launched a global search for a blood stem cell donor to save the life of his seriously ill 12-year-old daughter.

Arya Lloyd first complained of stomach pains in May this year, and initially her parents thought they were general growing pains.

But when the pains persisted, Arya was referred to St Mary's Hospital in Paddington, London, and was diagnosed with the blood disorder aplastic anaemia.

Doctors say her best chance of survival is through a blood stem transplant.

Her parents Geraint Lloyd, 45, a consultant general surgeon at the Lister Hospital in Stevenage, and dentist Brundha Lloyd, 47, have been told they would only be a 50% match at best and that Arya needs a 10/10 match.

Ordinarily the best match would be from a sibling, but she is an only child so her best hope now rests with a stranger.

Mr Lloyd, from Cambridge, said: "Our world was turned on its head when we were given Arya's devastating diagnosis.

"It is with us always, and we're doing all we can to provide her with a second chance of life.

"I am a surgeon who has spent half my life looking after people with serious medical problems and cancer, but nothing prepares you for this.

"The world is a very different place now we know Arya is so unwell."

The family is working with international blood cancer charity DKMS in search of a donor.

Arya's mixed heritage - being Indian and Caucasian - makes the search for a donor more challenging.

Mrs Lloyd has family in America and India, and DKMS has branches in both countries, so a global search to find Arya her match is on.

Although the UK has a diverse population, patients from a black, Asian or other minority background have a 20% chance of finding the best possible stem cell donor match, compared to 69% from northern European backgrounds, DKMS said.

Mr Lloyd said: "We're at the mercy of others right now. We need their support."

DKMS has reported a steep decline in new donors coming forward since March due to COVID-19.

EastEnders actor Priya Davdra is working with DKMS to encourage more people, particularly those from Asian communities, to sign up as potential blood stem cell donors.

"It broke my heart when I heard about Arya's situation," she said.

"To think what she and her family must be going through is just so awful."

She has signed up as a potential donor and urged others to do so.

DKMS is seeking potential blood stem cell donors from all backgrounds.

If you are aged between 17 and 55 and in good general health, you can support Arya and the other 2,000 people in need of a lifesaving transplant by registering online at dkms.org.uk/en/arya for a home swab kit

See the article here:
Arya Lloyd: Father launches global search for blood stem cell donor to save his 12-year-old daughter - Sky News

Blood Cancer: Science Reveal Five Easily Missed Signs of Leukemia – Science Times

By Stem Cell Doctors

Experts diagnose someone with a blood cancerapproximately every three minutes in the United States. Every year, new blood cancer reports account for10 percent of new diagnoses of cancer.

There are typically three separate types of blood cancers, according toExpress.co.uk. These include leukemia, lymphoma, and myeloma. Signs and symptoms vary based on the form of blood cancer an individual has.

Major factors in leukemia survival rates include early diagnosis and management. Read on to find out more about some of the signs of early blood cancer that you can never miss.

(Photo : Dan Kitwood/Getty Images/Cancer Research UK) CAMBRIDGE, UNITED KINGDOM - DECEMBER 09: A fridge of chemical solutions which contain nutrients that are needed to 'feed' cells and keep them alive for laboratory experiments, at the Cancer Research UK Cambridge Institute on December 9, 2014 in Cambridge, England. Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research. Its vision is to bring forward the day when all cancers are cured. They have saved millions of lives by discovering new ways to prevent, diagnose and treat cancer, and as such the survival rate in the UK has doubled in the last 40 years. Cancer Research UK funds over 4,000 scientists, doctors and nurses across the UK, more than 33,000 patients who join clinical trials each year and a further 40,000 volunteers that give their time to support the work.

According toHematology.org, most blood cancers begin in the bone marrow - where blood is made. These cancers disrupt the development and work of your blood. The stem cells transform into three types of blood cells-white, red, or platelets in the bone marrow.

When anyone has blood cancer, and irregular blood cell's development influences the regular output of blood cells. These cancer cells inhibit the regular functions of your blood such as preventing excessive bleeding or combating diseases. There are three major types of tumors in the blood: leukemia, lymphoma, and myeloma.

Leukemia is a disease that induces the massive development of irregular white blood cells in your blood marrow. This stops bacteria from being combated by the body. These cells often hinder platelets and red blood cells from being formed by the bone marrow.

Plasma cell cancer is myeloma. The antibodies in your body are produced by these white blood cells to combat and resist illnesses and diseases. This cancer can disrupt the immune system of your body and render you susceptible to infection.

Lymphoma hinders the lymphatic function that generates immune cells and removes the body from surplus fluids. Abnormal lymphocytes, along with other cells, can accumulate and gather in the lymph nodes. The body's immune system is weakened by these cancerous cells.

Blood cancer signs differ, like leukemia. Here are certain signs of blood cancer that you can look out for. Many of these signs may sound like the flu and maybe simple to ignore.

If the body produces leukemia, blood cells are destroyed by the disease, so it is impossible for your body to produce safe blood cells. You can experience anemia, and light skin is one of the major signs of anemia. Also, your hands can feel cold to the touch.

A typical symptom in certain diseases is exhaustion. You can see the doctor if you feel more worn out than usual and note a drastic difference in your energy.

Your blood cells aid the functioning of the immune system. The body's immune system does not normally work when certain cells are unhealthy, leading you to get sick more frequently. Frequent fevers and pneumonia are some of the most prominent first signs of leukemia.

You can also keep an eye on any shortness of breath if you are feeling energy depleted. You can take care if you feel short of breath any more quickly during physical exercise.

You can bleed more than usual because the body does not produce enough platelets. You might even more often get a bloody nose. Other modifications connected to your blood that you can look out for include:

No one is sure of what induces leukemia or other cancers of the blood, and there is no means of stopping it. Many factors in the environment, including smoking, pollution, and radiation, may lead to this disease's growth. The past of the family may also play a part in your chance of leukemia.

ALSO READ: Coronavirus Survivors Twice as Likely to Develop Mental Disorders - Study

Check out more news and information on Medicine and Healthon Science Times.

See original here:
Blood Cancer: Science Reveal Five Easily Missed Signs of Leukemia - Science Times

BioRestorative Therapies Emerges from Chapter 11 Reorganization Other OTC:BRTX – GlobeNewswire

By Adult Stem Cells

November 20, 2020 07:00 ET | Source: BioRestorative Therapies, Inc.

MELVILLE, N.Y., Nov. 20, 2020 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative or the Company) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that its amended joint plan of reorganization has become effective and it has emerged from Chapter 11 reorganization. Pursuant to the confirmed plan of reorganization, the Company has received $3,848,000 in financing. The confirmed plan of reorganization also provides for additional funding, subject to certain conditions, of $3,500,000 less the sum of the debtor-in-possession financing provided to the Company during the reorganization (approximately $1,227,000) and the costs incurred by the debtor-in-possession lender.

In connection with the reorganization, Lance Alstodt has been appointed the Companys President, Chief Executive Officer and Chairman of the Board. Mr. Alstodt said, This process has been a long and challenging journey for the Company. Im inspired by the great resolve and execution from our employees, professionals and investors. We are very pleased that all requirements have been met for us to emerge. Allowed creditor claims have been fully satisfied and, as importantly, our equity holders have retained their shares in this exciting new opportunity. We were able to preserve all of our intellectual property assets and look forward to initiating our Phase 2 clinical trial.

Based upon the Companys emergence from Chapter 11 reorganization, FINRA has removed the Q at the end of its trading symbol. Shareholders do not need to exchange their shares for new shares.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Disc/Spine Program (brtxDISC): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

Metabolic Program (ThermoStem): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT: Email: ir@biorestorative.com

BioRestorative Therapies, Inc.

Melville, New York, UNITED STATES

http://www.biorestorative.com

Formats available:

View post:
BioRestorative Therapies Emerges from Chapter 11 Reorganization Other OTC:BRTX - GlobeNewswire

Jakafi and Dacogen May Improve Overall Survival in Patients with MPN – Curetoday.com

By Adult Stem Cells

Results from a phase 2 study demonstrated that treatment with Jakafi (ruxolitinib) and Dacogen (decitabine) was well tolerated and contributed to favorable overall survival (OS) in patients with myeloproliferative neoplasm (MPN) in the accelerated or blast phase.

MPN is a blood cancer that develops when a stem cell mutation in the bone marrow leads to an overproduction of white cells, red cells and/or platelets. The accelerated phase of MPN refers to when 10% to 19% of blasts, or immature blood cells, are in the blood circulating through the body or in the bone marrow, whereas the blast phase refers to 20% or greater blasts in the circulating blood or bone marrow, according to the study published in Blood Advances.

This study was important, as patients with an antecedent (pre-existing) myeloproliferative neoplasm that evolves into an acute myeloid leukemia have a dismal prognosis of several months, and induction chemotherapy alone does not improve outcome unless followed by consolidation hematopoietic stem cell transplantation, Dr. John O. Mascarenhas, director of the adult leukemia program and leader of the myeloproliferative neoplasm clinical research program at Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, said in an interview with CURE.

The study authors previously assessed this therapy in a multicenter, phase 1 trial.

We had previously shown that the epigenetic modifying agent decitabine can be administered (on) an outpatient (basis) and improve outcome with a median survival of nine to 10 months, Mascarenhas said. This prospective, phase 2, multicenter, investigated-initiated trial built on the phase 1 trial of combination decitabine and ruxolitinib based on supportive preclinical data from the laboratory of our collaborator, (Dr.) Ross Levine.

In this current trial, 25 patients (median age, 71 years; 56% women) with MPN either in the accelerated phase (10 patients; median age, 70.1 years; 70% women) or blast phase (15 patients; median age, 71.6 years; 46.7% women) were treated with Jakafi and Dacogen. A 25 mg dose of Jakafi was administered orally twice per day for 28 days in addition to a 20 mg/m2 dose of Dacogen intravenously during days 8 through 12. After that first cycle, the dose of Jakafi was reduced to 10 mg.

The prespecified primary endpoint, or goal, was best response by six months, and the predetermined secondary endpoint focused on the safety and tolerability of Jakafi and Dacogen. Study authors defined OS as the time from the first dose of Jakafi to death from any cause.

During follow-up, 19 patients died from causes including respiratory failure, disease progression, sepsis and pneumonia. Patients in this study had a median OS of 9.5 months. Overall response rate, which included complete remission, incomplete platelet recovery and partial remission, occurred in 44% of patients. Response to this treatment was not linked with improved survival.

This combination is well tolerated and can provide spleen symptom benefit and survival advantage compared to cytotoxic chemotherapy, Mascarenhas said. This study supports the use of this approach to maintain ambulatory care of these very advanced patients with a limited lifespan. This is one therapeutic approach that is now included in the (National Comprehensive Cancer Network) guidelines.

Mascarenhas added that more research is needed in this area. Ultimately, we need to identify active agents that can fully eliminate the malignant hematopoietic stem cell and attain molecular remissions that afford patients long-term survival, he said. This is an ongoing area of active translational research of our group.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

See more here:
Jakafi and Dacogen May Improve Overall Survival in Patients with MPN - Curetoday.com

BRTX-100; the Story of BioRestorative Therapies Inc (OTCMKTS: BRTX) – MicroCap Daily

By Adult Stem Cells

Post Views: 2,586

BioRestorative Therapies Inc (OTCMKTS: BRTXQ) (BRTX) is soaring up the charts after it was revealed at 12.04 pm Wednesday afternoon the Company was emerging from bankruptcy. BRTXQ came to the attention of many penny stock speculators after the Company partnered on a new bankruptcy reorganization plan with one of its creditors Auctus Capital in which it would emerge from bankruptcy with the commons intact, ready to begin phase 2 trials and get BioRestorative back on a national stock exchange.

BioRestorative Therapies has received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs. BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. It is the Companys intend that the product be used for the non-surgical treatment of painful lumbosacral disc disorders.

BioRestorative Therapies Inc (OTCMKTS: BRTX) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: Disc/Spine Program (brtxDISC): Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders.

The BRTX-100 production process utilizes proprietary technology and involves collecting a patients bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patients damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The Company has received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs.

To Find out the inside Scoop on BioRestorative Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

Metabolic Program (ThermoStem): the Company is developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

BioRestorative owns a valuable intelectual property portfolio including unique international Stem Cell patents as well as 8 patents issued, in the United States and other countries, for the Companys brown fat technology related to BioRestoratives metabolic program (ThermoStem Program).

For More on BRTX Subscribe Right Now!

BioRestorative Therapies is making a powerful move up the charts after it was it was revealed at 12.04 pm Wednesday afternoon the Company was emerging from bankruptcy. This comes after the Company successfully entered into a reorganization plan with one of its creditors Auctus Capital after its March Bankruptcy filing in which the Company would emerge from bankruptcy with the commons intact, ready to begin their phase 2 trials and get BioRestorative back on a national stock exchange. BioRestorative Therapies has received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat persistent lower back pain due to painful degenerative discs. BRTX-100, is a product formulated from autologous (or a persons own) cultured mesenchymal stem cells collected from the patients bone marrow. It is the Companys intend that the product be used for the non-surgical treatment of painful lumbosacral disc disorders. We will be updating on BioRestorative when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with BioRestorative.

Disclosure: we hold no position in BRTX either long or short and we have not been compensated for this article.

Share.

Read the rest here:
BRTX-100; the Story of BioRestorative Therapies Inc (OTCMKTS: BRTX) - MicroCap Daily

Thanyapura, StemCells21 to offer premium stem cell treatments in Thailand – BSA bureau

By Induced Pluripotent Stem Cells

The partnership will offer premium stem cell treatments for various degenerative diseases, immune disorders, injuries and anti-ageing.

Thanyapura Sports and Health Resort, Phuket has partnered with StemCells21 (SC21), a medical biotech company based in Bangkok, Thailand. With over a decade of clinical history and 100 years of collective team experience, SC21 combines 21stcentury cellular medicine and cutting-edge supportive therapies to offer the highest quality stem cell treatments with Mesenchymal Stem Cells (MSCs) and Induced Pluripotent Stem Cells (iPSCs).

A first of its kind for Phuket, Thanyapura in partnership with SC21, will offer premium stem cell treatments for various degenerative diseases, immune disorders, injuries and anti-ageing. The treatments can also tackle a host of medical problems such as type 2 diabetes, osteoarthritis, chronic back pain and inflammatory lung diseases such as asthma and bronchitis, as well as strengthen body immunity and improve fertility.

In the sporting world, regenerative medicine is seen as a crucial component and can aid in optimising the human body to perform at a higher level, as well as being highly effective in the treatment of sports injuries through faster healing, reduced injury inflammation and the regeneration of injured tissue. The human-based regenerative therapy has been successful with high calibre athletes for endurance enhancement and lengthening professional careers by reducing injury rates.

Guests can book a free dedicated one-on-one consultation with a certified stem cell specialist for their first session. Those seeking longer-term treatments can book a discounted stay at Thanyapura to utilise its world-class facilities, award-winning vegan and vegetarian restaurants and lifestyle clinic.Team isexcited to facilitate their first clinic outside of Bangkok.

President & CEO of Thanyapura World, Philipp Graf von Hardenberg said, "Treatment packages can be customised from the number of Premium Grade (P1) MSCs to the treatment duration and include supportive therapies from a comprehensive health check-up to the highest standards of after-care services. Thanyapuras 360 approach will help in delivering better, longer-lasting outcomes for challenging conditions that conventional therapies often fail to address, such as stopping disease progression, as well as avoiding surgical intervention.

Go here to see the original:
Thanyapura, StemCells21 to offer premium stem cell treatments in Thailand - BSA bureau

→←